ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The advent of asciminib, a first‐in‐class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, has further expanded the therapeutic landscape of CML, providing a novel mechanism of action to overcome resistance and improve patient outcomes (Manley et al. 2020).